PATHOLOGIC STAGE III CUTANEOUS MELANOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE III CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE III CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE III CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to wipe out melanoma before surgery
Disease control OngoingThis study tests whether giving drug combinations before surgery can help people with high-risk stage III melanoma. The trial involves 59 participants receiving either targeted cancer drugs, immunotherapy drugs, or both for several weeks before their operation. Researchers want t…
Matched conditions: PATHOLOGIC STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Balancing act: fighting cancer while protecting a transplanted kidney
Disease control OngoingThis early-phase study is testing a combination of immunotherapy drugs (nivolumab and ipilimumab) along with standard transplant medications (tacrolimus and prednisone) in kidney transplant patients with advanced skin cancers that have spread or cannot be removed by surgery. The …
Matched conditions: PATHOLOGIC STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Can your diet boost cancer treatment? new study investigates
Disease control OngoingThis study is testing whether eating a high-fiber diet can improve gut health and help the immune system fight cancer in patients with advanced melanoma who are receiving standard immunotherapy. Fifty participants will be randomly assigned to follow either a high-fiber diet or a …
Matched conditions: PATHOLOGIC STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New cancer combo aims to supercharge immune system while taming side effects
Disease control OngoingThis study is testing a combination of three immunotherapy drugs—tocilizumab, ipilimumab, and nivolumab—in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. The main goal is to see if adding tocilizumab can help manage the serious side effects someti…
Matched conditions: PATHOLOGIC STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Facebook groups fight skin cancer in families
Prevention OngoingThis study is testing whether private Facebook groups can help young melanoma survivors and their close family members prevent future skin cancer. Researchers are comparing two types of groups: one focused on skin cancer education and one on general healthy living. The goal is to…
Matched conditions: PATHOLOGIC STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Prevention
Last updated Mar 30, 2026 14:34 UTC
-
Tracking the hidden toll: study maps immunotherapy side effects in cancer survivors
Knowledge-focused OngoingThis study observes melanoma survivors who have completed surgery and are receiving immunotherapy drugs to prevent cancer return. Researchers follow 126 patients for two years to track side effects, symptoms like fatigue and depression, and quality of life. The goal is to underst…
Matched conditions: PATHOLOGIC STAGE III CUTANEOUS MELANOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:01 UTC